Boehringer Ingelheim and Lilly initiate post-marketing trial with a planned enrollment of more than 8,000 adults with type 2 diabetes in 24 countries (Lilly)
Diabetes News Service
Glycosmedia is also available as an App:
For iPhone and iPad | For Android devices
Sponsorship and Advertising
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
